Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study was to analyze which step of the procedure of toxin botulinum injection is the most painful between skin break-in, electric stimulation, injection and needle withdrawal.
Post-stroke spasticity management by botulinum toxin injections may be limited by pain or discomfort at the injection side.
Particularly tracking by electrostimulation, but also skin puncture, toxin injection or needle withdrawal may be painful.
The objective of this study is to define an individual injection strategy in order to limit pain.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| spasticity post-stroke | pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pain rating during injection with botulinum toxin | Other | The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evolution of pain intensity during injection with botulinum toxin | Pain intensity in different steps of the procedure of toxin botulinum injection: skin break-in, electric stimulation, injection and needle withdrawal. | 30 min |
| Measure | Description | Time Frame |
|---|---|---|
| Hypoesthesia | Semmes Weinstein Monofilament Evaluation | 30 min |
| Neuropathic pain | DN4 (Neuropathic pain 4 questions) | 30 min |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Consecutive patients were assessed during routine botulinum toxin injection in the day clinic of our department
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dominic PERENNOU, MD, PhD | University Hospital, Grenoble | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D009128 | Muscle Spasticity |
| D020521 | Stroke |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009135 | Muscular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001905 | Botulinum Toxins |
| ID | Term |
|---|---|
| D008666 | Metalloendopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009140 | Musculoskeletal Diseases |
| D009122 | Muscle Hypertonia |
| D020879 | Neuromuscular Manifestations |
| D009422 | Nervous System Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D004798 |
| Enzymes |
| D045762 | Enzymes and Coenzymes |
| D045726 | Metalloproteases |
| D001426 | Bacterial Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001427 | Bacterial Toxins |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |